EA201690561A1 - Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i - Google Patents

Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i

Info

Publication number
EA201690561A1
EA201690561A1 EA201690561A EA201690561A EA201690561A1 EA 201690561 A1 EA201690561 A1 EA 201690561A1 EA 201690561 A EA201690561 A EA 201690561A EA 201690561 A EA201690561 A EA 201690561A EA 201690561 A1 EA201690561 A1 EA 201690561A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
peptidase
inhibitors
peptidylnitrile
dipopeptidyl
Prior art date
Application number
EA201690561A
Other languages
English (en)
Other versions
EA029030B1 (ru
Inventor
Конни Лауритсен
Джон Педерсен
Original Assignee
Прозюмекс А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозюмекс А/С filed Critical Прозюмекс А/С
Publication of EA201690561A1 publication Critical patent/EA201690561A1/ru
Publication of EA029030B1 publication Critical patent/EA029030B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к соединениям формулы (I) и их применению в качестве селективных ингибиторов дипептидилпептидазы I, а также к фармацевтическим композициям, содержащим указанные соединения, и к способам лечения с привлечением указанных соединений.
EA201690561A 2013-09-09 2014-09-08 Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i EA029030B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183519 2013-09-09
EP14151979 2014-01-21
PCT/EP2014/069088 WO2015032945A1 (en) 2013-09-09 2014-09-08 Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors

Publications (2)

Publication Number Publication Date
EA201690561A1 true EA201690561A1 (ru) 2016-07-29
EA029030B1 EA029030B1 (ru) 2018-01-31

Family

ID=51535425

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690561A EA029030B1 (ru) 2013-09-09 2014-09-08 Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i

Country Status (10)

Country Link
US (1) US9856228B2 (ru)
EP (1) EP3044214B1 (ru)
JP (1) JP6408008B2 (ru)
CN (1) CN105612149A (ru)
AU (1) AU2014317048B2 (ru)
CA (1) CA2923484C (ru)
DK (1) DK3044214T3 (ru)
EA (1) EA029030B1 (ru)
SG (1) SG11201601150WA (ru)
WO (2) WO2015032945A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201601150WA (en) 2013-09-09 2016-03-30 Prozymex As Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
NO2699580T3 (ru) 2014-01-24 2018-02-24
CA2978234C (en) * 2015-03-05 2023-05-02 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
CA2981732C (en) * 2015-04-07 2024-03-12 Boris Khalfin Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
MA52424A (fr) 2018-03-01 2021-01-06 Astrazeneca Ab Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010006110A (es) * 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
KR100903499B1 (ko) 2007-12-27 2009-06-18 엔에이치엔비즈니스플랫폼 주식회사 검색 의도 분류에 따른 광고 제공 방법 및 상기 방법을수행하기 위한 시스템
SG175090A1 (en) * 2009-05-07 2011-11-28 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
WO2012119941A1 (en) * 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
WO2012130299A1 (en) 2011-03-30 2012-10-04 Prozymex A/S Peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
SG11201601150WA (en) 2013-09-09 2016-03-30 Prozymex As Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors

Also Published As

Publication number Publication date
CA2923484C (en) 2022-09-06
US9856228B2 (en) 2018-01-02
DK3044214T3 (da) 2017-11-13
NZ718128A (en) 2021-04-30
CN105612149A (zh) 2016-05-25
WO2015032943A1 (en) 2015-03-12
EP3044214A1 (en) 2016-07-20
JP6408008B2 (ja) 2018-10-17
EA029030B1 (ru) 2018-01-31
WO2015032945A1 (en) 2015-03-12
SG11201601150WA (en) 2016-03-30
AU2014317048A1 (en) 2016-04-07
CA2923484A1 (en) 2015-03-12
EP3044214B1 (en) 2017-08-09
JP2016529306A (ja) 2016-09-23
AU2014317048B2 (en) 2018-05-10
US20160207900A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201891501A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201492002A1 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201690844A1 (ru) Ингибиторы gsk-3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title